Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 336

Similar articles for PubMed (Select 18394438)

1.

Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome.

Frere C, Cuisset T, Morange PE, Quilici J, Camoin-Jau L, Saut N, Faille D, Lambert M, Juhan-Vague I, Bonnet JL, Alessi MC.

Am J Cardiol. 2008 Apr 15;101(8):1088-93. doi: 10.1016/j.amjcard.2007.11.065. Epub 2008 Feb 6.

PMID:
18394438
2.

Genetic determined low response to thienopyridines is associated with higher systemic inflammation in smokers.

Shahabi P, Cuisset T, Stathopoulou MG, Morange PE, Grosdidier C, Herbeth B, Siest G, Alessi MC, Visvikis-Siest S.

Pharmacogenomics. 2015 Apr;16(5):459-69. doi: 10.2217/pgs.15.17.

PMID:
25916518
3.

Diversity of platelet function and genetic polymorphism in clopidogrel-treated Chinese patients.

Sun B, Li J, Dong M, Yang L, Wu C, Zhu L, Cong YL.

Genet Mol Res. 2015 Feb 13;14(1):1434-42. doi: 10.4238/2015.February.13.22.

4.

Differential impact of selective serotonin reuptake inhibitors on platelet response to clopidogrel: a randomized, double-blind, crossover trial.

Hirsh-Rokach B, Spectre G, Shai E, Lotan A, Ritter A, Al-Aieshy F, Malmström RE, Varon D, Alcalai R.

Pharmacotherapy. 2015 Feb;35(2):140-7. doi: 10.1002/phar.1542.

PMID:
25689244
5.

Comment on Xie et al.: The effects of CES1A2 A(-816)C and CYP2C19 loss-of-function polymorphisms on clopidogrel response variability among Chinese patients with coronary heart disease.

Bjerre D, Ferrero L, Madsen M, Hansen PR, Rasmussen HB; INDICES Consortium.

Pharmacogenet Genomics. 2015 Mar;25(3):147. doi: 10.1097/FPC.0000000000000114. No abstract available.

PMID:
25647335
6.

Routine screening for CYP2C19 polymorphisms for patients being treated with clopidogrel is not recommended.

Bhopalwala AM, Hong RA, Khan ZR, Valentin MR, Badawi RA.

Hawaii J Med Public Health. 2015 Jan;74(1):16-20.

7.

The relationship between on-clopidogrel platelet reactivity, genotype, and post-percutaneous coronary intervention outcomes in Chinese patients.

Tang N, Yin S, Sun Z, Xu X, Qin J.

Scand J Clin Lab Invest. 2015 May;75(3):223-9. doi: 10.3109/00365513.2014.993696. Epub 2015 Jan 16.

PMID:
25594796
8.

Prevalence and significance of CYP2C19*2 and CYP2C19*17 alleles in a New Zealand acute coronary syndrome population.

Larsen PD, Johnston LR, Holley A, La Flamme AC, Smyth L, Chua EW, Kennedy MA, Harding SA.

Intern Med J. 2015 May;45(5):537-45. doi: 10.1111/imj.12698.

PMID:
25583161
9.

[Population pharmacokinetics and pharmacodynamics of clopidogrel in patients with acute coronary syndrome].

Xie C, Ding XL, Xue L, Jiang B, Hang YF, Gao J, Miao LY.

Yao Xue Xue Bao. 2014 Oct;49(10):1426-32. Chinese.

PMID:
25577873
10.

Genetic polymorphisms of CYP2C19 2 and ABCB1 C3435T affect the pharmacokinetic and pharmacodynamic responses to clopidogrel in 401 patients with acute coronary syndrome.

Wang XQ, Shen CL, Wang BN, Huang XH, Hu ZL, Li J.

Gene. 2015 Mar 10;558(2):200-7. doi: 10.1016/j.gene.2014.12.051. Epub 2014 Dec 24.

PMID:
25542807
11.

[Effect of original and generic clopidogrel on prognosis in relation to different gene polymorphisms].

Mesitskaia DF, Nikitina IuM, Lomakin OV, Shchekochikhin DIu, Kopylov FIu.

Ter Arkh. 2014;86(9):77-82. Russian.

PMID:
25518510
12.

Influence of CYP2C19 polymorphisms on platelet reactivity and clinical outcomes in ischemic stroke patients treated with clopidogrel.

Qiu LN, Sun Y, Wang L, Han RF, Xia XS, Liu J, Li X.

Eur J Pharmacol. 2015 Jan 15;747:29-35. doi: 10.1016/j.ejphar.2014.11.037. Epub 2014 Dec 6.

PMID:
25489921
13.

Joint effects of CYP2C19*2 and smoking status on clopidogrel responsiveness in patients with acute coronary syndrome.

Peng L, Zhang L, Yang J, Wang X, Li X, Guo W, Zhang Y, Xu Q, Lu C, Yin T.

Int J Cardiol. 2015 Feb 1;180:196-8. doi: 10.1016/j.ijcard.2014.11.210. Epub 2014 Nov 27. No abstract available.

PMID:
25463363
14.

Post receptor determinants of acute platelet response to clopidogrel in patients with symptomatic myocardial ischemia.

Nooney VB, Hurst NL, Chirkov YY, De Caterina R, Horowitz JD.

Vascul Pharmacol. 2015 Feb-Mar;65-66:17-22. doi: 10.1016/j.vph.2014.11.003. Epub 2014 Nov 20.

PMID:
25460367
15.

VASP phosphorylation and genetic polymorphism for clopidogrel resistance in Chinese patients with non-cardioembolic ischemic stroke.

Zhang S, Lai X, Li W, Xiong Z, Xu A, Xu A, Huang L.

Thromb Res. 2014 Dec;134(6):1272-7. Epub 2014 Oct 12.

PMID:
25457586
16.

Effects of cytochrome P450 2C19 and paraoxonase 1 polymorphisms on antiplatelet response to clopidogrel therapy in patients with coronary artery disease.

Tresukosol D, Suktitipat B, Hunnangkul S, Kamkaew R, Poldee S, Tassaneetrithep B, Likidlilid A.

PLoS One. 2014 Oct 16;9(10):e110188. doi: 10.1371/journal.pone.0110188. eCollection 2014.

17.

Interaction between clopidogrel and smoking.

Mendelsohn C.

Aust Fam Physician. 2014 Aug;43(8):503. No abstract available.

PMID:
25252366
18.

[Required knowledge for stroke specialists (2) platelet activation and regulation in patients with ischemic stroke].

Nagao T.

No Shinkei Geka. 2014 Sep;42(9):879-85. Japanese. No abstract available.

PMID:
25179203
19.

Mean platelet volume may not be related to clopidogrel resistance in patients with acute coronary syndrome. Author's reply.

Özpelit E.

Anadolu Kardiyol Derg. 2014 Jun;14(4):406-7. No abstract available.

PMID:
25133282
20.

Single nucleotide polymorphism of CYP3A5*3 contributes to clopidogrel resistance in coronary artery disease patients among Tamilian population.

Priyadharsini R, Shewade DG, Subraja K, Ravindra BK, Umamaheswaran G, Dkhar SA, Satheesh S, Sridhar MG, Narayan SK, Adithan C.

Mol Biol Rep. 2014 Nov;41(11):7265-71. doi: 10.1007/s11033-014-3613-8. Epub 2014 Aug 12.

PMID:
25112801
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk